Medical Devices - Minimally Invasive Surgery and Interventional Medicine
Strategic Profile
AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. The Med Tech segment showed exceptional performance with 26.1% growth, marking its fourth consecutive quarter of over 20% growth. The company maintains a debt-free balance sheet and is transitioning toward profitability with improving gross margins and positive cash flow expectations.
Cyborg Score Rationale
The Med Tech segment showed exceptional performance with 26.1% growth to $35.3 million, marking its fourth consecutive quarter of over 20% growth. Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher compared to the first quarter of fiscal 2025. The Company maintains a debt-free balance sheet.
Top Insights
Med Tech segment now drives significant growth with 26.1% YoY expansion in Q1 FY2026, markedly outpacing overall company growth of 12.2%
Gross margin expansion of 90-260 basis points driven by higher-margin Med Tech mix and operational efficiencies despite tariff headwinds
Pipeline momentum: First patient enrollments in AMBITION BTK and RECOVER-AV trials; NanoKnife PRESERVE study published with strong clinical outcomes
Debt-free balance sheet with $41.6M cash; company expects to achieve cash flow positive status for full FY2026
Named Competitors
Auryon Atherectomy System — Competing atherectomy platform for peripheral vascular disease
Mechanical thrombectomy systems — Competing mechanical aspiration and removal systems for clot management
Irreversible electroporation ablation — Niche competitor with established NanoKnife platform for soft tissue ablation
Recent Developments
(January 2026) FDA IDE approval for APEX-Return study and PAVE clinical study; modified AlphaVac F1885 510(k) clearance
(January 2026) Concluded long-standing patent litigation with Bard; raised FY2026 revenue guidance to $312-314M
(October 2025) NanoKnife PRESERVE study published in European Urology; first patient enrollments in AMBITION BTK and RECOVER-AV trials
(January 2026) CEO Jim Clemmer announced intention to retire upon successor appointment (anticipated FY2027)
Open the full interactive AngioDynamics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.